• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际核医学与分子影像学会(EANM)-美国核医学与分子影像学会(SNMMI)-国际磁共振医学学会(ISMRM)关于肿瘤PET/MRI的共识推荐

International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.

作者信息

Veit-Haibach Patrick, Ahlström Håkan, Boellaard Ronald, Delgado Bolton Roberto C, Hesse Swen, Hope Thomas, Huellner Martin W, Iagaru Andrei, Johnson Geoffrey B, Kjaer Andreas, Law Ian, Metser Ur, Quick Harald H, Sattler Bernhard, Umutlu Lale, Zaharchuk Greg, Herrmann Ken

机构信息

Joint Department Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, Toronto General Hospital, 1 PMB-275, 585 University Avenue, Toronto, Ontario, M5G 2N2, Canada.

Joint Department of Medical Imaging, University of Toronto, Toronto, Canada.

出版信息

Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3513-3537. doi: 10.1007/s00259-023-06406-x. Epub 2023 Aug 25.

DOI:10.1007/s00259-023-06406-x
PMID:37624384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10547645/
Abstract

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. The merged International Society for Magnetic Resonance in Medicine (ISMRM) is an international, nonprofit, scientific association whose purpose is to promote communication, research, development, and applications in the field of magnetic resonance in medicine and biology and other related topics and to develop and provide channels and facilities for continuing education in the field.The ISMRM was founded in 1994 through the merger of the Society of Magnetic Resonance in Medicine and the Society of Magnetic Resonance Imaging. SNMMI, ISMRM, and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine and/or magnetic resonance imaging. The SNMMI, ISMRM, and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and/or magnetic resonance imaging and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice guideline, representing a policy statement by the SNMMI/EANM/ISMRM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI, ISMRM, and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging and magnetic resonance imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized. These guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI, the ISMRM, and the EANM caution against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine includes both the art and the science of the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.

摘要

核医学与分子影像学会(SNMMI)是一个成立于1954年的国际科学和专业组织,旨在促进核医学的科学、技术及实际应用。欧洲核医学协会(EANM)是一个专业的非营利性医学协会,它促进了全球范围内在核医学领域追求临床和研究卓越的个人之间的交流。EANM成立于1985年。合并后的国际医学磁共振学会(ISMRM)是一个国际非营利性科学协会,其宗旨是促进医学和生物学领域磁共振及其他相关主题的交流、研究、开发和应用,并为该领域的继续教育开发和提供渠道及设施。ISMRM于1994年通过医学磁共振学会和磁共振成像学会的合并而成立。SNMMI、ISMRM和EANM的成员包括专门从事核医学和/或磁共振成像研究与实践的医生、技术人员和科学家。SNMMI、ISMRM和EANM将定期为核医学实践制定新的指南,以帮助推动核医学和/或磁共振成像科学的发展,并提高全球范围内对患者的服务质量。现有实践指南将在其五周年或如有必要更早的时候进行审查,以便酌情修订或更新。每一项实践指南,作为SNMMI/EANM/ISMRM的政策声明,都经历了一个全面的共识过程,在此过程中它受到了广泛的审查。SNMMI、ISMRM和EANM认识到,如每份文件所述,安全有效地使用诊断性核医学成像和磁共振成像需要特定的培训、技能和技术。未提供这些服务的实体无权复制或修改已发布的实践指南。这些指南是一种教育工具,旨在帮助从业者为患者提供适当的护理。它们不是僵化的实践规则或要求,也无意,也不应被用于确立护理的法律标准。出于这些原因以及下文所述的原因,SNMMI、ISMRM和EANM告诫不要在对从业者的临床决策提出质疑的诉讼中使用这些指南。关于任何特定程序或行动方案是否恰当的最终判断必须由医生或医学物理学家根据所呈现的所有情况做出。因此,并不意味着与指南不同的方法本身低于护理标准。相反,当从业者合理判断患者的病情、可用资源的限制或指南发布后知识或技术的进步表明需要采取不同的行动方案时,尽责的从业者可能会负责任地采取与指南中规定的不同的行动方案。医学实践包括疾病预防、诊断、缓解和治疗的艺术与科学。人类病情的多样性和复杂性使得不可能总是做出最恰当的诊断或确定地预测对治疗的特定反应。因此,应该认识到遵循这些指南并不能确保准确的诊断或成功的结果。所能期望的只是从业者将根据当前知识、可用资源和患者需求采取合理的行动方案,以提供有效和安全的医疗护理。这些指南的唯一目的是帮助从业者实现这一目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d224/10547645/a98ef59fecb3/259_2023_6406_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d224/10547645/a98ef59fecb3/259_2023_6406_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d224/10547645/a98ef59fecb3/259_2023_6406_Fig1_HTML.jpg

相似文献

1
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.国际核医学与分子影像学会(EANM)-美国核医学与分子影像学会(SNMMI)-国际磁共振医学学会(ISMRM)关于肿瘤PET/MRI的共识推荐
Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3513-3537. doi: 10.1007/s00259-023-06406-x. Epub 2023 Aug 25.
2
SNMMI Procedure Standard/EANM Practice Guideline for Brain [F]FDG PET Imaging, Version 2.0.SNMMI脑部[F]FDG PET成像程序标准/EANM实践指南,第2.0版。
J Nucl Med. 2024 Oct 17. doi: 10.2967/jnumed.124.268754.
3
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.《EANM/SNMMI/ANZSNM 联合实践指南/程序标准:在实体瘤患者接受免疫调节治疗期间推荐使用 [F]FDG PET/CT 成像(第 1.0 版)》
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2323-2341. doi: 10.1007/s00259-022-05780-2. Epub 2022 Apr 4.
4
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric F-FDG PET/CT for Oncology 1.0.SNMMI 程序标准/EANM 实践指南:儿科肿瘤 1.0 版 F-FDG PET/CT
J Nucl Med. 2021 Jan;62(1):99-110. doi: 10.2967/jnumed.120.254110.
5
Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts.欧洲核医学协会(EANM)关于血管移植物感染成像的循证指南。
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3430-3451. doi: 10.1007/s00259-022-05769-x. Epub 2022 Apr 4.
6
The SNMMI and EANM practice guideline for renal scintigraphy in adults.美国核医学与分子影像学会和欧洲核医学协会成人肾闪烁显像实践指南。
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2218-2228. doi: 10.1007/s00259-018-4129-6. Epub 2018 Aug 30.
7
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.EANM 实践指南:经动脉放射性化合物治疗肝癌和肝转移瘤。
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699. doi: 10.1007/s00259-021-05600-z. Epub 2022 Feb 11.
8
AAPM medical physics practice guideline 7.a.: Supervision of medical physicist assistants.美国医学物理学会医学物理实践指南7.a:医学物理师助理的监督
J Appl Clin Med Phys. 2020 Jul;21(7):11-15. doi: 10.1002/acm2.12774. Epub 2019 Dec 4.
9
AAPM medical physics practice guideline 3.b.: Levels of supervision for medical physicists in clinical training.美国医学物理学家协会医学物理实践指南3.b:临床培训中医务物理学家的监督级别。
J Appl Clin Med Phys. 2021 Jun;22(6):11-15. doi: 10.1002/acm2.13258. Epub 2021 May 20.
10
AAPM Medical physics practice guideline 15.A: Peer review in clinical physics.AAPM 医学物理实践指南 15.A:临床物理的同行评审。
J Appl Clin Med Phys. 2023 Oct;24(10):e14151. doi: 10.1002/acm2.14151. Epub 2023 Sep 14.

引用本文的文献

1
The safety and clinical impact of ultra-low-dose FDG-PET imaging in pregnancy-associated breast cancer: the experience of a major tertiary oncology referral centre in the UK and suggested imaging protocol.超低剂量氟代脱氧葡萄糖正电子发射断层显像(FDG-PET)成像在妊娠相关乳腺癌中的安全性及临床影响:英国一家大型三级肿瘤转诊中心的经验及建议的成像方案
Nucl Med Commun. 2025 Aug 1;46(8):772-779. doi: 10.1097/MNM.0000000000001997. Epub 2025 Jun 4.
2
Whole-body MRI Versus [ 18 F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas : A Comparative Study.全身MRI与[18F]FDG PET/CT在浆细胞瘤诊断和监测中的比较研究
Clin Nucl Med. 2025 Aug 1;50(8):695-706. doi: 10.1097/RLU.0000000000005954. Epub 2025 May 16.
3

本文引用的文献

1
68 Ga-FAPI-04 PET/CT in Selected Breast Cancer Patients With Low FDG Affinity : A Head-to-Head Comparative Study.68Ga-FAPI-04 PET/CT 用于 FDG 亲和力低的特定乳腺癌患者:一项头对头对比研究。
Clin Nucl Med. 2023 Sep 1;48(9):e420-e430. doi: 10.1097/RLU.0000000000004751. Epub 2023 Jun 23.
2
What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature.放射性核素标记 FAPI PET 在乳腺癌中的应用:文献系统综述。
Ann Nucl Med. 2023 Aug;37(8):442-450. doi: 10.1007/s12149-023-01852-x. Epub 2023 Jun 21.
3
The potential application of MR-derived ADCmin values from Ga-DOTATATE and F-FDG dual tracer PET/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors.
PET/MRI is superior to PET/CT in detecting oesophago and gastric carcinomas: a meta-analysis.
PET/MRI在检测食管癌和胃癌方面优于PET/CT:一项荟萃分析。
Cancer Imaging. 2025 Apr 7;25(1):50. doi: 10.1186/s40644-025-00871-3.
4
The frequency and characterization of ovarian metastasis from nonovarian cancers using 18F-fluorodeoxyglucose PET/CT.使用18F-氟脱氧葡萄糖PET/CT对非卵巢癌卵巢转移的频率及特征分析
BJR Open. 2025 Mar 18;7(1):tzaf004. doi: 10.1093/bjro/tzaf004. eCollection 2025 Jan.
5
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?FAPI放射性药物在实体肿瘤的核肿瘤学与诊疗一体化中的应用:我们离攻克癌症的特征更近了吗?
Ann Nucl Med. 2025 May;39(5):407-423. doi: 10.1007/s12149-025-02022-x. Epub 2025 Mar 11.
6
Phase I study of [Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects.[镓]镓-HX01针对健康受试者和恶性肿瘤受试者中整合素αvβ3和CD13的I期研究。
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1293-1304. doi: 10.1007/s00259-024-07002-3. Epub 2024 Nov 29.
7
Advanced Imaging for Localized Prostate Cancer.局限性前列腺癌的先进成像技术
Cancers (Basel). 2024 Oct 15;16(20):3490. doi: 10.3390/cancers16203490.
8
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.个性化 PET 成像在肿瘤学中的应用:对荟萃分析的伞式综述,以指导合适的放射性药物选择和适应证。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):208-224. doi: 10.1007/s00259-024-06882-9. Epub 2024 Sep 11.
9
Automatic assessment of body composition in children with lymphoma: results of a [F]FDG-PET/MR study.淋巴瘤患儿身体成分的自动评估:一项[F]FDG-PET/MR研究的结果
Eur Radiol. 2025 Jan;35(1):341-350. doi: 10.1007/s00330-024-10957-4. Epub 2024 Jul 16.
10
Application of PET/MRI in Gynecologic Malignancies.PET/MRI在妇科恶性肿瘤中的应用。
Cancers (Basel). 2024 Apr 12;16(8):1478. doi: 10.3390/cancers16081478.
镓标记的DOTATATE和氟代脱氧葡萄糖(F-FDG)双示踪剂PET/MR成像中磁共振成像衍生的最小表观扩散系数(ADCmin)值在评估胰腺神经内分泌肿瘤分级和分期方面替代F-FDG PET的潜在应用。
EJNMMI Res. 2023 Feb 8;13(1):10. doi: 10.1186/s13550-023-00960-z.
4
Advanced imaging and theranostics in thyroid cancer.甲状腺癌的高级影像学与治疗学。
Curr Opin Endocrinol Diabetes Obes. 2022 Oct 1;29(5):456-465. doi: 10.1097/MED.0000000000000740. Epub 2022 Jul 2.
5
Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial.铜-生长抑素释放肽类似物-蛙皮素PET-CT成像在雌激素/孕激素受体阳性、HER2阴性转移性乳腺癌患者分期中的应用:一项I期试验的安全性、剂量测定及可行性
Pharmaceuticals (Basel). 2022 Jun 22;15(7):772. doi: 10.3390/ph15070772.
6
Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature.生长抑素受体靶向PET成像在脑膜瘤诊断、放射治疗计划制定及诊疗一体化中的应用:文献系统综述
Diagnostics (Basel). 2022 Jul 8;12(7):1666. doi: 10.3390/diagnostics12071666.
7
Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement.用于前列腺活检的男性中,镓-PSMA-11正电子发射断层扫描/磁共振成像与多参数磁共振成像的比较:原发肿瘤定位及阅片者间一致性
Eur J Hybrid Imaging. 2022 Jul 18;6(1):14. doi: 10.1186/s41824-022-00135-4.
8
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.高级别胶质瘤治疗反应监测生物标志物:关于支持在临床中使用先进MRI技术的证据以及最新的从 bench 到 bedside 进展的立场声明。第1部分:灌注和扩散技术。
Front Oncol. 2022 Mar 3;12:810263. doi: 10.3389/fonc.2022.810263. eCollection 2022.
9
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics.高级别胶质瘤治疗反应监测生物标志物:关于支持在临床中使用先进MRI技术的证据以及最新的从 bench 到 bedside 进展的立场声明。第2部分:光谱学、化学交换饱和、多参数成像和放射组学。
Front Oncol. 2022 Feb 28;11:811425. doi: 10.3389/fonc.2021.811425. eCollection 2021.
10
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.新型正电子发射断层扫描放射性示踪剂在神经内分泌肿瘤成像中的应用。
Curr Treat Options Oncol. 2022 May;23(5):703-720. doi: 10.1007/s11864-022-00967-z. Epub 2022 Mar 24.